U. S. Opens Door to Chinese Pharma Deals: What's Behind the Shift? A recent surge in biopharma stocks in Hong Kong has been driven by reports of potential changes in U. S.
regulations, sparking speculation about the future of Sino American collaborations in pharmaceutical research and development. The apparent move by the U. S.
Treasury Department to allow American companies to continue licensing most drugs from Chinese firms is a significant shift in policy with far reaching implications for both sides.